



IPO : Sai Parenteral's Limited

March 2026

Snapshot

Sai Parenteral's Limited is an India-based pharmaceutical company engaged in the manufacturing and development of drug formulations, with a focus on sterile injectables and contract development and manufacturing services (CDMO). Incorporated in 2001 and headquartered in Telangana, the company operates multiple manufacturing facilities and serves both domestic and international markets. It has a diversified product portfolio and emphasizes quality compliance with regulatory standards. The company is planning an initial public offering to raise funds for expansion and business growth. Backed by experienced promoters and supported by subsidiaries, it aims to strengthen its position in the pharmaceutical manufacturing sector.

Company Vision

Sai Parenteral's Limited aims to become a globally recognized pharmaceutical company by delivering high-quality, affordable, and innovative drug formulations. Its vision is centered on strengthening its presence in regulated and semi-regulated markets while expanding its CDMO capabilities. The company seeks to invest in advanced manufacturing technologies, enhance research and development, and maintain strict compliance with international quality standards. By fostering long-term partnerships and focusing on customer-centric solutions, it aspires to create sustainable growth and value for stakeholders. Additionally, the company is committed to improving healthcare outcomes by ensuring reliable access to safe and effective medicines worldwide.

Growth Prospects

Sai Parenteral's Limited has strong growth prospects driven by increasing global demand for sterile injectables and outsourcing trends in pharmaceutical manufacturing. The company is well-positioned to benefit from the rising preference for contract development and manufacturing services (CDMO), especially from regulated markets. Planned capacity expansions and investments in advanced technologies are expected to enhance production capabilities and efficiency. Its diversified product portfolio and focus on quality compliance support entry into new geographies. Additionally, strategic partnerships and a growing international presence can drive revenue growth, while the IPO proceeds are likely to strengthen financial flexibility and support long-term expansion initiatives.

Opening Date	Tuesday, March 24, 2026
Closing Date	Friday, March 27, 2026
Price Band	Rs. 372 to Rs. 392 per share
Bid Lot	38 Shares
Face Value	Rs. 5 per share
Issue Size	1,04,28,288 shares (aggregating up to Rs. 409 Cr)
Fresh Issue	72,70,408 shares (aggregating up to Rs. 285 Cr)
Offer for Sale	31,57,880 shares (aggregating up to Rs. 124 Cr)
Registrar	Bigshare Services Pvt.Ltd.

Key Financials

Amount in cr.	30-Sep-25	FY2025	FY2024	FY 2023
Assets	376.2	272.4	268.1	134.0
Total Income	89.4	163.7	155.2	97.0
Profit After Tax	7.8	14.4	8.4	4.4
EBITDA	16.2	39.4	31.7	17.6
NET Worth	209.4	95.8	76.4	31.5
Reserves and Surplus	188.8	80.4	61.3	24.3
Total Borrowing	76.1	94.0	118.8	68.6

Risk Assessment

Sai Parenteral's Limited faces several risks that could impact its performance. The company operates in a highly regulated pharmaceutical industry, making it vulnerable to compliance failures and regulatory approvals across different markets. Dependence on a limited number of products and customers may affect revenue stability. Intense competition from domestic and global players can pressure margins and market share. Additionally, fluctuations in raw material prices and supply chain disruptions may impact costs and operations. The company's expansion plans and IPO execution also carry financial and operational risks, while foreign exchange fluctuations could affect earnings from international business.